Table 2.
Association between baseline characteristics and the progression of disease.
| Characteristic | Number (%) | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|---|
| Odds Ratio (95% Confidence Interval (Cl)) | p-Value | Odds Ratio (95% Cl) | p-Value | ||
| Age | |||||
| ≤60 years | 21 (65.6) | Reference | |||
| >60 years | 11 (34.4) | 1.6 (0.37–6.95) | 0.53 | ||
| FIGO stage | |||||
| IIIC | 26 (81.3) | Reference | |||
| IV | 6 (18.8) | 0.5 (0.08–3.22) | 0.466 | ||
| Histology | |||||
| Serous/others | 20 (62.5) | Reference | Reference | ||
| Mucinous/clear cell | 4 (12.5) | 0.67 (0.08–5.75) | 0.712 | 0.41 (0.03–5.25) | 0.494 |
| Endometrioid | 8 (25) | 0.1 (0.01–0.93) | 0.043 | 0.11 (0.01–1.35) | 0.085 |
| Size of residual tumor | |||||
| ≤1 cm | 20 (62.5) | Reference | Reference | ||
| >1 cm | 12 (37.5) | 3.71 (0.82–16.84) | 0.089 | 11.6 (1.07–125.92) | 0.044 |
| Site of residual tumor | |||||
| Lower abdomen | 12 (37.5) | Reference | |||
| Upper abdomen | 11 (34.4) | 1.67 (0.31–9.01) | 0.553 | ||
| Whole abdomen | 9 (28.1) | 4 (0.64–25.02) | 0.138 | ||
| Time of treatment | |||||
| 18 weeks | 18 (56.3) | Reference | Reference | ||
| 18–21 weeks | 11 (34.4) | 2.75 (0.58–12.98) | 0.201 | 5.17 (0.63–42.45) | 0.126 |
| >24 weeks | 3 (9.4) | 0.79 (0.06–10.38) | 0.855 | 0.10 (0.004–2.26) | 0.146 |
| ECOG | |||||
| 0–1 | 30 (93.8) | Reference | |||
| 2–3 | 2 (6.3) | 1.14 (0.07–20.02) | 0.927 | ||
Data are presented as numbers (%).